Anne Tybjærg-Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Tybjærg-Hansen has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Børge Grønne Nordestgaard
Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
12 shared publications Ruth Frikke-Schmidt
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Denmark; The Copenhagen General Population Study, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
12 shared publicationsBørge G. Nordestgaard
The Copenhagen General Population Study, Denmark; Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
11 shared publicationsMette Christoffersen
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Denmark
10 shared publications- Stefan Stender
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
10 shared publications Bo Kobberø Lauridsen
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
5 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 149, 106834
Lifestyle characteristics and plasma biomarkers for risk of MASLD differ by sex in the general population
- 16 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 149, 106834
Open AccessLifestyle characteristics and plasma biomarkers for risk of MASLD differ by sex in the general population
- Open Access
- 17 October 2025
- Published by Elsevier in Atherosclerosis
- Vol. 411, 120551
Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease
- 17 October 2025
- Published by Elsevier in Atherosclerosis
- Vol. 411, 120551
Open AccessMetabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease
- Open Access
- 3 September 2025
- Published by Elsevier in Atherosclerosis
- Vol. 409, 120507
Repurposing statin treatment for the prevention of gallstone disease
- 3 September 2025
- Published by Elsevier in Atherosclerosis
- Vol. 409, 120507
Open AccessRepurposing statin treatment for the prevention of gallstone disease
- 1 February 2025
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 10 (2) , 155-163
Transthyretin Tetramer Destabilization and Increased Mortality in the General Population
Importance: Transthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.Objective: To test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.Design, Setting, and Participants: In this cohort study including individuals aged 20 to 80 years, genetic data were analyzed from 2 similar prospective studies of the Danish general population, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS). Observational data from a subsample of the same studies where transthyretin was measured consecutively were also analyzed. In both studies, individuals were followed up from the examination date (1991-1994 in CCHS and 2003-2015 in CGPS) until death or the end of follow-up in December 2018. Data were analyzed from November 1, 2023, to August 15, 2024.Exposures: Missense variants in TTR associated with increasing transthyretin tetramer destabilization in primary genetic analyses, and plasma transthyretin level in secondary observational analyses.Main Outcomes and Measures: All-cause and cardiovascular mortality identified from the national Danish Civil Registration System and the national Danish Register of Causes of Death.Results: A total of 102 204 individuals (median [IQR] age, 57 [47-66] years; 56 445 [55%] female) were included. Median follow-up was 10 years (range, P for trend = .01), and 1.63 (95% CI, 0.92-2.89) and 2.23 (95% CI, 0.78-6.34) for cardiovascular mortality (P for trend = .06). Furthermore, compared with p.T139M, plasma transthyretin decreased stepwise by TTR genotype: −18% for noncarriers and −29% for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, p.D119N; P for trend < .001). Therefore, genetically determined, increasingly lower plasma transthyretin could be considered a surrogate marker for transthyretin tetramer destabilization. Observationally, among 19 619 individuals, noncarriers with plasma transthyretin concentrations less than 20 mg/dL vs 20 to 40 mg/dL had HRs of 1.12 (95% CI, 1.02-1.23) for all-cause mortality and 1.16 (95% CI, 0.97-1.39) for cardiovascular mortality.Conclusions and Relevance: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.
- 1 February 2025
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 10 (2) , 155-163
Transthyretin Tetramer Destabilization and Increased Mortality in the General Population
Importance: Transthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.Objective: To test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.Design, Setting, and Participants: In this cohort study including individuals aged 20 to 80 years, genetic data were analyzed from 2 similar prospective studies of the Danish general population, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS). Observational data from a subsample of the same studies where transthyretin was measured consecutively were also analyzed. In both studies, individuals were followed up from the examination date (1991-1994 in CCHS and 2003-2015 in CGPS) until death or the end of follow-up in December 2018. Data were analyzed from November 1, 2023, to August 15, 2024.Exposures: Missense variants in TTR associated with increasing transthyretin tetramer destabilization in primary genetic analyses, and plasma transthyretin level in secondary observational analyses.Main Outcomes and Measures: All-cause and cardiovascular mortality identified from the national Danish Civil Registration System and the national Danish Register of Causes of Death.Results: A total of 102 204 individuals (median [IQR] age, 57 [47-66] years; 56 445 [55%] female) were included. Median follow-up was 10 years (range, P for trend = .01), and 1.63 (95% CI, 0.92-2.89) and 2.23 (95% CI, 0.78-6.34) for cardiovascular mortality (P for trend = .06). Furthermore, compared with p.T139M, plasma transthyretin decreased stepwise by TTR genotype: −18% for noncarriers and −29% for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, p.D119N; P for trend < .001). Therefore, genetically determined, increasingly lower plasma transthyretin could be considered a surrogate marker for transthyretin tetramer destabilization. Observationally, among 19 619 individuals, noncarriers with plasma transthyretin concentrations less than 20 mg/dL vs 20 to 40 mg/dL had HRs of 1.12 (95% CI, 1.02-1.23) for all-cause mortality and 1.16 (95% CI, 0.97-1.39) for cardiovascular mortality.Conclusions and Relevance: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.
- 22 October 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (10-12) , 591-596
Does SLC39A8 Ala391Thr Confer Risk of Chronic Liver Disease?
Manganese is an important cofactor for numerous biological processes, including defense against reactive oxygen species. A common genetic variant in the manganese transporter SLC39A8 (p.Ala391Thr) has been associated with lower blood levels of manganese and with increases in markers of liver cell damage. Whether the variant confers an increased risk of liver disease is unclear. We tested the association of this variant with biochemical, imaging, and clinical hepatic traits and outcomes in large general population cohorts totaling up to one million individuals, including 991 cases with hepatocellular carcinoma (HCC) and 7191 cases with cirrhosis. We found that the Thr-allele of p.Ala391Thr was associated with slightly higher plasma alanine transaminase and aspartate transaminase, markedly higher corrected T1 on hepatic magnetic resonance imaging, a presumed marker of liver inflammation, and with lower hepatic computed tomography attenuation. However, the variant was not associated with hepatic fat content or with the risk of HCC or cirrhosis. In conclusion, SLC39A8 p.Ala391Thr is associated with biochemical and imaging markers of hepatic inflammation, but the variant does not confer a higher risk of chronic liver disease. We hypothesize that the associations with hepatic imaging traits are due to lower hepatic manganese levels in carriers of the variant. Antioxid. Redox Signal. 41, 591–596.
- 22 October 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (10-12) , 591-596
Does SLC39A8 Ala391Thr Confer Risk of Chronic Liver Disease?
Manganese is an important cofactor for numerous biological processes, including defense against reactive oxygen species. A common genetic variant in the manganese transporter SLC39A8 (p.Ala391Thr) has been associated with lower blood levels of manganese and with increases in markers of liver cell damage. Whether the variant confers an increased risk of liver disease is unclear. We tested the association of this variant with biochemical, imaging, and clinical hepatic traits and outcomes in large general population cohorts totaling up to one million individuals, including 991 cases with hepatocellular carcinoma (HCC) and 7191 cases with cirrhosis. We found that the Thr-allele of p.Ala391Thr was associated with slightly higher plasma alanine transaminase and aspartate transaminase, markedly higher corrected T1 on hepatic magnetic resonance imaging, a presumed marker of liver inflammation, and with lower hepatic computed tomography attenuation. However, the variant was not associated with hepatic fat content or with the risk of HCC or cirrhosis. In conclusion, SLC39A8 p.Ala391Thr is associated with biochemical and imaging markers of hepatic inflammation, but the variant does not confer a higher risk of chronic liver disease. We hypothesize that the associations with hepatic imaging traits are due to lower hepatic manganese levels in carriers of the variant. Antioxid. Redox Signal. 41, 591–596.
- Open Access
- 5 July 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (39) , 4196-4198
Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important?
Left panel: results of three recent randomized trials of triglyceride-lowering drugs on lipids, lipoproteins, apolipoprotein B (apoB), and C-reactive protein (CRP), and on major adverse cardiovascular events (MACE) in patients at high cardiovascular risk with mild to moderately elevated triglycerides, low LDL cholesterol (LDL-C), and on statin therapy. REDUCE-IT randomized 8179 patients to 2 g of icosapent ethyl (EPA) twice daily vs. mineral oil.1 STRENGTH randomized 13 078 patients to 4 g per day of a carboxylic acid formulation of EPA and docosahexanoic acid (DHA) vs. corn oil.2 PROMINENT randomized 10 497 patients with type 2 diabetes to pemafibrate (a selective PPARα modulator) 0.2 mg twice daily vs. placebo.3 Although all active treatments were associated with reductions in triglycerides, the effects on other lipids, lipoproteins, apoB, and CRP differed between studies. Only REDUCE-IT was associated with a robust 25% reduction in cardiovascular risk; however, this might be partially driven by a 10% increase in LDL-C and a 32% increase in CRP caused by the comparator mineral oil.4 Right panel: results of the present study by Björnson et al.5 The study included individual participant data from the UK Biobank (n = 502 460) with available genetic data and standard lipid profiles including apoB to identify all single nucleotide polymorphisms (SNPs) associated with TRL/remnant cholesterol (remnant-C) and LDL-C in GWAS analyses. To investigate the per-particle atherogenicity (change in CHD risk per unit change in particle number, i.e. per unit change in apoB) of TRL/remnants and LDL, the effect size (β coefficient) of each SNP on TRL/remnant-C and LDL-C (markers of the abundance of particles) was plotted against its effect size on apoB (a marker of particle number). These SNPs fell into two groups, one with a much greater effect on TRL/remnant-C per unit difference in apoB than the other. Accordingly, SNPs were divided into two clusters. Cluster 1 contained SNPs involved in receptor-mediated clearance that affected LDL-C more than TRL/remnant-C (median ratio = 0.19), whereas cluster 2 contained SNPs with effects on triglyceride lipolysis and had a much greater effect on TRL/remnant-C (median ratio = 0.59). The CHD risk per standard deviation (SD) higher apoB was considerably higher for cluster 2 vs. cluster 1 SNPs, implying that TRL/remnant particles have a substantially greater per particle atherogenicity than LDL. RCT, randomized clinical trial; TG, triglyceride; non-HDL-C, non-HDL cholesterol (total cholesterol minus HDL cholesterol); HR, hazard ratio; TRL, triglyceride-rich lipoprotein; remnant-C, remnant cholesterol; OR, odds ratio; CHD, coronary heart disease; ND, no data; GWAS, genome-wide association study.
- 5 July 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (39) , 4196-4198
Open AccessTriglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important?
Left panel: results of three recent randomized trials of triglyceride-lowering drugs on lipids, lipoproteins, apolipoprotein B (apoB), and C-reactive protein (CRP), and on major adverse cardiovascular events (MACE) in patients at high cardiovascular risk with mild to moderately elevated triglycerides, low LDL cholesterol (LDL-C), and on statin therapy. REDUCE-IT randomized 8179 patients to 2 g of icosapent ethyl (EPA) twice daily vs. mineral oil.1 STRENGTH randomized 13 078 patients to 4 g per day of a carboxylic acid formulation of EPA and docosahexanoic acid (DHA) vs. corn oil.2 PROMINENT randomized 10 497 patients with type 2 diabetes to pemafibrate (a selective PPARα modulator) 0.2 mg twice daily vs. placebo.3 Although all active treatments were associated with reductions in triglycerides, the effects on other lipids, lipoproteins, apoB, and CRP differed between studies. Only REDUCE-IT was associated with a robust 25% reduction in cardiovascular risk; however, this might be partially driven by a 10% increase in LDL-C and a 32% increase in CRP caused by the comparator mineral oil.4 Right panel: results of the present study by Björnson et al.5 The study included individual participant data from the UK Biobank (n = 502 460) with available genetic data and standard lipid profiles including apoB to identify all single nucleotide polymorphisms (SNPs) associated with TRL/remnant cholesterol (remnant-C) and LDL-C in GWAS analyses. To investigate the per-particle atherogenicity (change in CHD risk per unit change in particle number, i.e. per unit change in apoB) of TRL/remnants and LDL, the effect size (β coefficient) of each SNP on TRL/remnant-C and LDL-C (markers of the abundance of particles) was plotted against its effect size on apoB (a marker of particle number). These SNPs fell into two groups, one with a much greater effect on TRL/remnant-C per unit difference in apoB than the other. Accordingly, SNPs were divided into two clusters. Cluster 1 contained SNPs involved in receptor-mediated clearance that affected LDL-C more than TRL/remnant-C (median ratio = 0.19), whereas cluster 2 contained SNPs with effects on triglyceride lipolysis and had a much greater effect on TRL/remnant-C (median ratio = 0.59). The CHD risk per standard deviation (SD) higher apoB was considerably higher for cluster 2 vs. cluster 1 SNPs, implying that TRL/remnant particles have a substantially greater per particle atherogenicity than LDL. RCT, randomized clinical trial; TG, triglyceride; non-HDL-C, non-HDL cholesterol (total cholesterol minus HDL cholesterol); HR, hazard ratio; TRL, triglyceride-rich lipoprotein; remnant-C, remnant cholesterol; OR, odds ratio; CHD, coronary heart disease; ND, no data; GWAS, genome-wide association study.
- Open Access
- 24 May 2023
- Published by Elsevier in Atherosclerosis
- Vol. 376, 26-33
Plasma TSH and cardiovascular disease in the general population: A Mendelian randomization study of 105,224 individuals
- 24 May 2023
- Published by Elsevier in Atherosclerosis
- Vol. 376, 26-33
Open AccessPlasma TSH and cardiovascular disease in the general population: A Mendelian randomization study of 105,224 individuals
- Open Access
- 4 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (39) , 3957-3959
Pharmacogenetics-guided CETP inhibition: an open question?
Top left panel: the dal-OUTCOMES trial included 15 871 patients after a recent acute coronary syndrome randomized to dalcetrapib vs. placebo and followed for a median of 31 months. The study was stopped due to futility. The primary composite endpoint was a major adverse cardiovascular event defined as: a composite of death from coronary heart disease, a major non-fatal coronary event (myocardial infarction, hospitalization for unstable angina with objective evidence of acute myocardial ischaemia, or cardiac arrest with resuscitation), or ischaemic stroke. Top right panel: the post-hoc pharmacogenomic substudy of dal-OUTCOMES included 5749 patients after a recent acute coronary syndrome randomized to dalcetrapib vs. placebo and genotyped for ADCY9 rs1967309 G>A, which was the lead variant identified in a genome-wide association study of the dalcetrapib arm of the study (n = 2842). The primary composite endpoint was a major adverse cardiovascular event defined as: coronary heart disease death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal ischaemic stroke, unstable angina, or unanticipated coronary revascularization. Bottom panel: the dal-GenE trial in the study by Tardif et al. included 6147 patients after acute coronary syndrome, who were homozygous for the minor A-allele (=AA genotype) of the ADCY9 rs1967309 variant. The AA homozygotes were randomized to dalcetrapib vs. placebo and followed for a median of 40.1 months. The primary composite endpoint was a major adverse cardiovascular event defined as: cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. MACE = major adverse cardiovascular event; ADCY9 = adenylate cyclase type 9 gene; HR = hazard ratio.
- 4 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (39) , 3957-3959
Open AccessPharmacogenetics-guided CETP inhibition: an open question?
Top left panel: the dal-OUTCOMES trial included 15 871 patients after a recent acute coronary syndrome randomized to dalcetrapib vs. placebo and followed for a median of 31 months. The study was stopped due to futility. The primary composite endpoint was a major adverse cardiovascular event defined as: a composite of death from coronary heart disease, a major non-fatal coronary event (myocardial infarction, hospitalization for unstable angina with objective evidence of acute myocardial ischaemia, or cardiac arrest with resuscitation), or ischaemic stroke. Top right panel: the post-hoc pharmacogenomic substudy of dal-OUTCOMES included 5749 patients after a recent acute coronary syndrome randomized to dalcetrapib vs. placebo and genotyped for ADCY9 rs1967309 G>A, which was the lead variant identified in a genome-wide association study of the dalcetrapib arm of the study (n = 2842). The primary composite endpoint was a major adverse cardiovascular event defined as: coronary heart disease death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal ischaemic stroke, unstable angina, or unanticipated coronary revascularization. Bottom panel: the dal-GenE trial in the study by Tardif et al. included 6147 patients after acute coronary syndrome, who were homozygous for the minor A-allele (=AA genotype) of the ADCY9 rs1967309 variant. The AA homozygotes were randomized to dalcetrapib vs. placebo and followed for a median of 40.1 months. The primary composite endpoint was a major adverse cardiovascular event defined as: cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. MACE = major adverse cardiovascular event; ADCY9 = adenylate cyclase type 9 gene; HR = hazard ratio.
- 27 May 2022
- Published by Springer Nature
- p. 429-446
Polygenic Risk Scores
- 9 April 2022
- Published by Springer Nature in Hepatology International
- Vol. 16 (3) , 702-711
A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population
Background A genetic variant in the manganese transporter SLC30A10 (rs188273166, p.Thr95Ile) was associated with increased plasma alanine transaminase (ALT) in a recent genome-wide association study in the UK Biobank (UKB). The aims of the present study were to test the association of rs188273166 with ALT in an independent cohort, and to begin to assess the clinical, hepatic, and biochemical phenotypes associated with the variant. Methods We included n = 334,886 white participants from UKB, including 14,462 with hepatic magnetic resonance imaging (MRI), and n = 113,612 individuals from the Copenhagen City Heart Study and the Copenhagen General Population Study combined. Results Genotyping SLC30A10 p.Thr95Ile identified 816 heterozygotes in the UKB and 111 heterozygotes in the Copenhagen cohort. Compared to noncarriers, heterozygotes had 4 and 5 U/L higher levels of ALT in the UKB and Copenhagen cohort, respectively, and 3 U/L higher plasma aspartate transaminase and gamma-glutamyl transferase in the UKB. Heterozygotes also had higher corrected T1 on liver MRI, a marker of hepatic inflammation (p = 4 × 10–7), but no change in MRI-quantified steatosis (p = 0.57). Plasma manganese was within the normal range in nine heterozygotes that provided new blood samples. SLC30A10 p.Thr95Ile heterozygotes had an eightfold increased risk of biliary tract cancer in UKB (p = 4 × 10–7), but this association was not replicated in the Copenhagen cohort. Conclusions SLC30A10 p.Thr95Ile was associated with elevated liver enzymes in two large general population cohorts, and with MRI-quantified hepatic inflammation. Graphical abstract A rare genetic variant (p.Thr95Ile) in the manganese transporter SLC30A10 is associated with elevated plasma alanine transaminase (ALT) and higher corrected T1 on liver MRI, markers of liver inflammation. These data support that the variant may increase the risk of liver disease.
- 9 April 2022
- Published by Springer Nature in Hepatology International
- Vol. 16 (3) , 702-711
A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population
Background A genetic variant in the manganese transporter SLC30A10 (rs188273166, p.Thr95Ile) was associated with increased plasma alanine transaminase (ALT) in a recent genome-wide association study in the UK Biobank (UKB). The aims of the present study were to test the association of rs188273166 with ALT in an independent cohort, and to begin to assess the clinical, hepatic, and biochemical phenotypes associated with the variant. Methods We included n = 334,886 white participants from UKB, including 14,462 with hepatic magnetic resonance imaging (MRI), and n = 113,612 individuals from the Copenhagen City Heart Study and the Copenhagen General Population Study combined. Results Genotyping SLC30A10 p.Thr95Ile identified 816 heterozygotes in the UKB and 111 heterozygotes in the Copenhagen cohort. Compared to noncarriers, heterozygotes had 4 and 5 U/L higher levels of ALT in the UKB and Copenhagen cohort, respectively, and 3 U/L higher plasma aspartate transaminase and gamma-glutamyl transferase in the UKB. Heterozygotes also had higher corrected T1 on liver MRI, a marker of hepatic inflammation (p = 4 × 10–7), but no change in MRI-quantified steatosis (p = 0.57). Plasma manganese was within the normal range in nine heterozygotes that provided new blood samples. SLC30A10 p.Thr95Ile heterozygotes had an eightfold increased risk of biliary tract cancer in UKB (p = 4 × 10–7), but this association was not replicated in the Copenhagen cohort. Conclusions SLC30A10 p.Thr95Ile was associated with elevated liver enzymes in two large general population cohorts, and with MRI-quantified hepatic inflammation. Graphical abstract A rare genetic variant (p.Thr95Ile) in the manganese transporter SLC30A10 is associated with elevated plasma alanine transaminase (ALT) and higher corrected T1 on liver MRI, markers of liver inflammation. These data support that the variant may increase the risk of liver disease.